Pain and Fatigue Improvements in Patients Treated with Repository Corticotropin Injection Across Five Indications: A Narrative Review

Cynthia Girman · Mary P. Panaccio · Kyle Hayes · John Niewoehner · George J. Wan

Received: March 10, 2022 / Accepted: April 29, 2022 / Published online: May 30, 2022 © The Author(s) 2022

ABSTRACT

Repository corticotropin injection (RCI; Acthar® Gel) is approved by the US Food and Drug Administration (FDA) for use in 19 indications, including for the treatment of selected patients with rheumatoid arthritis (RA), systemic lupus erythematosus (SLE), symptomatic sarcoidosis, uveitis, and keratitis. Despite treatment with disease-modifying antirheumatic drugs, many patients with RA, SLE, and other chronic inflammatory rheumatic diseases continue to be affected by severe pain and fatigue, indicating a need for other therapies. To examine the clinical data regarding the impact of RCI treatment on pain and fatigue in selected populations, this review included English-language peer-reviewed publications of clinical trials of any size and cohort studies with more than 10 patients that included pain and/or fatigue based on patient-reported outcomes (PROs) and/or physician-assessed measures in adults following treatment with RCI for RA, SLE, symptomatic sarcoidosis, uveitis, or keratitis. Literature searches identified eight studies that met these criteria. Four studies (reported in five publications) were in patients with RA or SLE, two in patients with sarcoidosis, one in patients with uveitis, and one in patients with noninfectious keratitis. Across the different types of studies assessed (clinical trials, chart reviews, real-world evidence), the results were consistent with respect to the impact of RCI treatment on improving pain and fatigue. As summarized in this review, data from patient- and physician-reported outcome measures in eight studies demonstrate that, in addition to improving more traditional efficacy measures, RCI may also improve pain and fatigue in patients with RA, SLE, symptomatic sarcoidosis, uveitis, and noninfectious keratitis.

PLAIN LANGUAGE SUMMARY

Rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE) are chronic autoimmune diseases. Clinical studies of drugs for these diseases do not often ask patients how they feel after treatment. Despite treatment, many people with these diseases have pain and feel tired. Repository corticotropin injection (RCI) is a prescription drug for patients with RA, SLE, and other chronic immune diseases. We reviewed the results of published studies with data on pain and fatigue from patients treated with RCI. Four studies were in patients with RA or SLE. Two studies were in
patients with symptomatic sarcoidosis. One study was in patients with uveitis. One study was in patients with noninfectious keratitis. These eight studies show that adding RCI to standard treatment lowers pain and fatigue in some patients. It would be helpful to measure pain and fatigue in future clinical studies of drugs for patients with chronic immune diseases.

**Keywords:** Acthar® Gel; Fatigue; Keratitis; Pain; RCI; Repository corticotropin injection; Rheumatoid arthritis; Sarcoidosis; Systemic lupus erythematosus; Uveitis

### Key Summary Points

#### Why carry out this study?

Despite use of disease-modifying antirheumatic drug (DMARD) therapy, many patients with rheumatoid arthritis (RA), systemic lupus erythematosus (SLE), and other chronic immune-mediated diseases continue to be affected by severe pain and fatigue [1–7]. Other therapies are needed to alleviate the high burden of pain and fatigue experienced by these patients despite treatment with biologics.

Repository corticotropin injection (RCI; Acthar® Gel) is a naturally sourced mixture of adrenocorticotropic hormone analogues and other pituitary peptides. RCI is approved by the US Food and Drug Administration (FDA) for use in 19 indications, including for the treatment of selected patients with RA, SLE, keratitis, uveitis, and symptomatic sarcoidosis [8]. Results from several clinical trials support the use of RCI as treatment for patients with RA, SLE, sarcoidosis, and noninfectious keratitis [9–16]. A prospective, single-group open-label study of RCI in eight patients with refractory RA reported statistically significant improvements in the primary endpoints of Ritchie–Camp articular index tender joint count and swollen joint count and in the total disease activity score for RA (DAS28) at 12 weeks; patient and physician global visual analog scales (VASs) also showed significant improvement at 12 weeks [9].

A prospective single-group study of RCI reported that 67% of patients with active RA and inadequate response to conventional disease-modifying antirheumatic drug (cDMARD) and at least three biologic DMARDs (bDMARDs) met the primary endpoint of adequate response, defined as greater than 1.2 point reduction in DAS28 with C-reactive protein (DAS28-CRP) at 12 weeks compared with baseline [10]. In a randomized, placebo-controlled withdrawal trial of RCI, 259 adults with active RA were treated with open-label RCI for 12 weeks; patients who had achieved low disease activity (LDA) were then randomized to RCI or placebo twice weekly for a 12-week double-blind period [11]. At the end of the double-blind period (24 weeks), 61.0% of patients in the RCI group versus 42.1% in the placebo group ($P = 0.019$)

#### What was learned from the study?

Across various studies, treatment with RCI was associated with improvements in patient- and physician-assessed pain and fatigue outcomes in patients with RA, SLE, symptomatic sarcoidosis, uveitis, and keratitis.

Pain and fatigue are important measures to consider for inclusion alongside conventional efficacy assessments in future clinical trials.

### INTRODUCTION

Despite use of disease-modifying antirheumatic drug (DMARD) therapy, many patients with rheumatoid arthritis (RA), systemic lupus erythematosus (SLE), and other chronic immune-mediated diseases continue to be affected by severe pain and fatigue [1–7]. Other therapies are needed to alleviate the high burden of pain and fatigue experienced by these patients despite treatment with biologics.

Repository corticotropin injection (RCI; Acthar® Gel) is a naturally sourced mixture of adrenocorticotropic hormone analogues and other pituitary peptides. RCI is approved by the US Food and Drug Administration (FDA) for use in 19 indications, including for the treatment of selected patients with RA, SLE, keratitis, uveitis, and symptomatic sarcoidosis [8]. Results from several clinical trials support the use of RCI as treatment for patients with RA, SLE, sarcoidosis, and noninfectious keratitis [9–16]. A prospective, single-group open-label study of RCI in eight patients with refractory RA reported statistically significant improvements in the primary endpoints of Ritchie–Camp articular index tender joint count and swollen joint count and in the total disease activity score for RA (DAS28) at 12 weeks; patient and physician global visual analog scales (VASs) also showed significant improvement at 12 weeks [9].

A prospective single-group study of RCI reported that 67% of patients with active RA and inadequate response to conventional disease-modifying antirheumatic drug (cDMARD) and at least three biologic DMARDs (bDMARDs) met the primary endpoint of adequate response, defined as greater than 1.2 point reduction in DAS28 with C-reactive protein (DAS28-CRP) at 12 weeks compared with baseline [10]. In a randomized, placebo-controlled withdrawal trial of RCI, 259 adults with active RA were treated with open-label RCI for 12 weeks; patients who had achieved low disease activity (LDA) were then randomized to RCI or placebo twice weekly for a 12-week double-blind period [11]. At the end of the double-blind period (24 weeks), 61.0% of patients in the RCI group versus 42.1% in the placebo group ($P = 0.019$).
maintained DAS28-ESR LDA (i.e., less than 3.2); similarly, 85.7% of patients in the RCI group versus 65.8% in the placebo group maintained Clinical Disease Activity Index (CDAI) LDA (i.e., less than or equal to 10) \( (P = 0.004) \).

A randomized double-blind trial of RCI versus placebo in 169 patients with active SLE and moderate to severe rash and/or arthritis by British Isles Lupus Assessment Group (BILAG)-2004 showed significant improvements in clinically important secondary endpoints of change from baseline to week 16 in 28 swollen joint count/tender joint count and cutaneous lupus erythematosus disease area and severity index (CLASI)-Activity scores [14]. According to post hoc analyses, patients treated with RCI were more likely than patients who had received placebo to achieve BILAG-based combined lupus assessment (BICLA) at weeks 4, 12, and 20. Also, RCI-treated patients with baseline SLEDAI-2 K \( \geq 10 \) and CLASI-Activity \( \geq 11 \) had greater SRI-4 responses. These results support the utility of RCI for treating patients with persistently active SLE. Patients with higher levels of SLE disease activity appeared to benefit the most from RCI.

Similarly, a randomized comparison of two RCI doses in patients with chronic pulmonary sarcoidosis who were receiving prednisone found significant decreases from baseline in prednisone dosage and improvements in pulmonary function, chest imaging, health-related quality of life, and fatigue for the 16 patients who persisted with 24 weeks of RCI treatment [15]. A prospective, open-label, single-arm phase 4 trial in patients with noninfectious keratitis reported that at week 12 of RCI therapy, 50% of patients had clinically important improvements in the primary endpoint, which was defined as the proportion of patients with at least a 12-point improvement in the symptom bother domain of the Impact of Dry Eye on Everyday Life (IDEEL) questionnaire at week 12 [16].

Real-world experience with RCI has been reported in case series in patients with psoriatic arthritis and SLE [17, 18]; in retrospective chart reviews in patients with sarcoidosis, RA, various rheumatologic diseases, uveitis, SLE, and dermatomyositis/polymyositis (DM/PM) [7, 19–22]; and in claims database analyses in patients with RA, other rheumatologic conditions, and SLE [23, 24]. These types of studies show that in routine clinical practice, patients who receive RCI tend to have difficult-to-treat disease and have tried multiple available alternative treatments without successful resolution of symptoms.

The purpose of this narrative review is to summarize the published clinical data regarding the impact of RCI treatment on pain and fatigue in patients with RA, SLE, symptomatic sarcoidosis, uveitis, and keratitis and to describe characteristics of patients who might benefit from RCI treatment.

**METHODS**

To identify relevant studies published in peer-reviewed journals, we searched PubMed, BIOSIS Previews, International Pharmaceutical Abstracts, Current Contents, and Embase with the terms “repository corticotropin injection” OR “ACTHAR Gel.” This literature review included English-language, peer-reviewed, published research reports of prospective clinical trials of any size and cohort studies (prospective and retrospective) with more than 10 patients that had patient-reported outcomes (PROs) and/or physician-assessed measures related to pain and/or fatigue in adults following treatment with RCI for RA, SLE, symptomatic sarcoidosis, uveitis, or keratitis. We excluded studies written in languages other than English, case reports and case series with 10 or fewer patients, as well as studies published only as abstracts presented at conferences.

Data from the studies that met the inclusion criteria were extracted using a standardized form and summarized in the tables included in this manuscript. This article is based on previously conducted studies and does not involve any new studies in humans or animals performed by any of the authors.
RESULTS

Reviewed Literature

Our literature searches identified eight studies that have published patient- or physician-reported data on pain or fatigue outcomes following treatment with RCI in patients with RA, SLE, symptomatic sarcoidosis, uveitis, and noninfectious keratitis. The findings from these studies are summarized below and in Tables 1, 2, and 3.

PRO tools used in the studies summarized in this report include the functional assessment of chronic illness therapy-fatigue (FACIT-F) [11, 12]; the lupus quality of life (LupusQOL) instrument, which includes pain-specific and fatigue-specific domains [25]; the fatigue assessment scale (FAS) [15]; patient assessment of pain by VAS (VAS pain) [22, 26]; and for uveitis and keratitis, the ocular discomfort score (ODS) [16]; four-symptom questionnaire (assessing dryness, grittiness, burning, stinging) [16]; and eye-specific VAS measures (assessing eye dryness, burning/stinging, itching, foreign body sensation, eye discomfort, photophobia, pain) [16]. Burning and stinging may be considered indicators of pain in patients with keratitis. Some studies captured pain and fatigue as a subset of other outcome measures such as change in patients’ overall health after RCI initiation (e.g., overall symptoms; lung function; inflammation; QOL; fatigue) [27] and physicians’ assessments of patient’s status and type of improvement observed after RCI treatment (i.e., improvements in vision, pain, vitreous haze, vitreous flare, and macular edema as well as reduction in background medication use) [21].

Impact of RCI on Pain and Fatigue in RA and SLE

Four studies (reported in five publications) included findings on PRO pain or fatigue measures in patients with RA or SLE (Table 1) [11, 12, 22, 25, 26]. Fleischmann et al. [11] used the patient-reported FACIT-F instrument to measure fatigue at baseline and at days 14 and 28 of treatment as part of a randomized withdrawal study of RCI compared with placebo. The study included 259 patients with active RA despite treatment with a stable dose of prednisone (or an equivalent) and one or two conventional synthetic disease-modifying antirheumatic drugs (csDMARDs) or one biologic DMARD (bDMARD). The study consisted of a 12-week open-label period with all patients (n = 259) receiving RCI (80 U) twice per week, followed by a 12-week double-blind placebo controlled comparator arm of RCI (80 U) twice per week for patients who had achieved LDA (DAS28-ESR score < 3.2) during the open-label portion (n = 77 for each cohort). The enrolled patients (median age, 51 years) were predominantly women (89%), with a mean DAS28-ESR of 6.3, well above the > 5.1 American College of Rheumatology (ACR) threshold for high disease activity [29]. Most patients were being concomitantly treated with methotrexate (96%) and with a nonbiologic DMARD (86%). During the 12-week RCI open-label period, mean FACIT-F scores significantly decreased from baseline to weeks 4, 8, and 12 (all P < 0.001). During the double-blind period, patients in both the RCI and placebo groups generally maintained improvements in FACIT-fatigue, with no statistically significant differences between the groups. Post hoc PRO analyses from the same trial showed significantly greater improvements (P < 0.0001) in patient-reported pain VAS and FACIT-F from baseline to weeks 12 among RCI responders (DAS28-ESR score < 3.2) compared with nonresponders in the open-label RCI treatment period [26]. Furthermore, in multivariable linear regression analyses, improvements from baseline in patient-reported pain VAS and FACIT-F correlated with significant decreases in total joint count, DAS28-ESR, and clinical disease activity index (CDAI).

A retrospective electronic medical record (EMR) analysis by Hayes et al. [22] used the US United Rheumatology-Normal Integrated Community Evidence (UR-NICE™) database to assess the real-world experience of 114 patients with RA during the unit of analysis is days before (pre-index) and after (post-index) RCI initiation. The UR-NICE™ database includes
| Study | Objective, design, and treatment | Outcomes and sample size | Key inclusion/exclusion criteria | Patient baseline characteristics | Fatigue outcomes | Pain outcomes |
|-------|----------------------------------|--------------------------|---------------------------------|---------------------------------|-----------------|--------------|
| RA    | **Fleischmann et al., 2020 [11]** | Primary endpoint: Proportion of patients who achieved DAS28-ESR < 3.2 at week 12 in part 1 of study (open-label part) | Inclusion: Age ≥ 18 years; met 2010 ACR/EULAR criteria for active RA (DAS28-ESR > 3.2), despite treatment with a stable dose of prednisone (or equivalent) and 1 or 2 csDMARDs or 1 bDMARD | All enrolled patients | None |
|       |                                  | Fatigue and/or pain outcome(s): FACIT-fatigue | Exclusion: Any rheumatic autoimmune disease or inflammatory joint disease other than RA | Mean age ± SD 51 ± 12 years | Mean FACIT-F scores: baseline: 22.8; week 4: 17.8 (vs baseline: P < 0.001); week 8: 16.2 (vs baseline: P < 0.001); week 12: 13.9 (vs baseline: P < 0.001) | None |
|       |                                  | No. of patients: N = 259, completed the open-label part (n = 235); achieved LDA at week 12 (n = 163); randomized to RCI (n = 77) and placebo (n = 77); completed the randomized part (RCI, n = 71; placebo, n = 56) | | Gender: female (89%); male (11%) | Double-blind period: Improvement on FACIT-F generally maintained in both groups throughout double-blind period | Pain VAS (mean ± SD): Index ± 7 days (6.7 ± 2.4); postindex (5.6 ± 2.9); (mean ± SD decrease 1.1 ± 2.8; P = 0.0056); MCID for pain VAS is 0.5–1.1 according to Wolfe et al., 2007 [30] |
|       |                                  | Open-label period: | | Methotrexate use: Prior (98%); concurrent (90%) | No significant differences RCI vs placebo |
|       |                                  | Mean DAS28-ESR ± SD 6.3 ± 1.0 | | Mean DAS28-ESR ± SD 6.3 ± 1.0 | |
|       |                                  | Mean age ± SD 152 ± 117 days from RCI start to last RCI prescription | | Mean DAS28-ESR ± SD 6.3 ± 1.0 | |
| RA    | **Hayes et al., 2021 [22]**     | Primary endpoint: No predefined primary endpoint/outcome | Inclusion: Prescribed RCI between December 6, 2013, and June 5, 2019; no evidence of prior RCI use; ≥ 1 diagnosis of RA at any time before index date; > 1 record with any activity (diagnosis, medication, procedure, biometric) in database > 180 days before and > 180 days after index date | Mean age ± SD 60.1 ± 11.0 years |
|       |                                  | Fatigue and/or pain outcome: Pain VAS | Exclusion: Not reported | Sex: % female (81%); male (19%) |
|       |                                  | No. of patients: N = 114 | | DMDARD, % patients: Any (90%); bDMARDs (74%); csDMARDs (68%); tsDMARDs (15%); ntDMARDs (13%) |
|       |                                  | | | Other treatments, %: Glucocorticoids (92%); NSAIDs (68%); opioids (59%) |
|       |                                  | | | CDAL, mean ± SD, 29.7 ± 16.4; high activity range is 22.1–76.0 according to Aletaha et al., 2005 [28] and Singh et al., 2016 [29] | |
Table 1 continued

| Study                                    | Objective, design, and treatment                                                                 | Outcomes and sample size                                      | Key inclusion/exclusion criteria                                | Patient baseline characteristics                        | Fatigue outcomes                                                                 | Pain outcomes                                                                 |
|------------------------------------------|------------------------------------------------------------------------------------------------|--------------------------------------------------------------|----------------------------------------------------------------|-----------------------------------------------------------|---------------------------------------------------------------------------------|--------------------------------------------------------------------------------|
| Fleischmann et al., 2021 [26]            | **Objective**: To determine the correlation between the clinical response to RCI treatment and improvements in PROs | **Primary endpoint**: None in post hoc analysis; see above, Fleischmann et al., 2020 [11] | **Inclusion**: See entry above at Fleischmann et al., 2020 [11] | See above, Fleischmann et al., 2020 [11]                   | Mean change from baseline to week 12 in FACIT-F: Responder (n = 160) −10.3 (95% CI −50.8 to −43.8) vs nonresponder (n = 95) −20.3 (95% CI −25.5 to −15.1); P < 0.0001 | Mean change from baseline to week 12 in pain VAS: Responder (n = 163) −47.3 (95% CI −50.8 to −43.8) vs nonresponder (n = 95) −20.3 (95% CI −25.5 to −15.1); P < 0.0001 |
|                                          | **Design**: Post hoc analysis of randomized, placebo-controlled withdrawal study listed above at Fleischmann et al., 2020 [11] | **Fatigue and/or pain outcome(s)**: Pain-VAS with MCID threshold indicating improvement ≥ 10 mm decrease [30, 32]; FACIT-F with MCID ≥ 3-point decrease [33] | **Exclusion**: See entry above at Fleischmann et al., 2020 [11] |                                                                                                           | By multivariable linear regression analysis: Change from baseline values in FACIT-F correlated with significant decreases in TJC, DAS28-ESR, and CDAI |
|                                          | **Treatment**: See above Fleischmann et al., 2020 [31]                                                                                           | **No. of patients**: Enrolled (N = 259); completed the open-label part (n = 235); achieved LDA at week 12 (n = 163) |                                                                  |                                                                                                           |                                                                                 |

SLE

| Fiechtner and Montroy, 2014 [12]         | **Objective**: To examine the efficacy and safety of RCI for reducing severity of active flares in patients receiving conventional SLE treatment regimens | **Primary endpoint**: Changes in baseline in SLEDAI-2 K score to month 3 and month 6 | **Inclusion**: Age 18–75 years; met ACR criteria for SLE; chronic, moderately-to-severely active disease; disease flare while receiving standard treatment for SLE | **Mean age**: 49 years; Sex: female (100%) | Mean FACIT-F (comparisons vs baseline): Baseline (30.7); day 14 (20.0; P < 0.01); day 28 (20.5; P < 0.01) | None                                                                         |
|                                          | **Design**: Prospective, open-label, phase 4 trial                                                                                              | **Fatigue and/or pain outcome(s)**: FACIT-fatigue             | **Exclusion**: Receiving new oral prednisone therapy or change in current oral prednisone dose |                                                                                                           |                                                                                 |
|                                          | **Treatment**: 80 U daily for 10 days with optional 5-day rescue period for partial or nonresponders                                              | **No. of patients**: N = 10                                   |                                                                  |                                                                                                           |                                                                                 |
### Table 1 continued

| Study | Objective, design, and treatment | Outcomes and sample size | Key inclusion/exclusion criteria | Patient baseline characteristics | Fatigue outcomes | Pain outcomes |
|-------|----------------------------------|--------------------------|----------------------------------|---------------------------------|-----------------|--------------|
| Askane et al., 2021 [25] | Objective: To analyze PRO results and report post hoc analyses to further characterize RCI-dependent effects on QOL and work productivity in patients with higher disease activity. Design: Secondary and post hoc analyses of Askane et al. 2020 [14]. Randomized, double-blind placebo-controlled trial. Treatment: RCI or placebo: 80 U every other day through week 4, then twice per week for 20 more weeks (total 24 weeks). | Primary endpoints: Proportion of patients who achieved SRI-4 response (4-point reduction from baseline in SLEDAI-2 K, with no new BILAG A score and ≤ 1 new BILAG B organ domain score compared with baseline, and with ≤ 10% increase from baseline in PGA) at week 16. Fatigue and/or pain outcomes: Change from baseline to week 24 in Lupus QOL and WPAI-Lupus questionnaire. | Inclusion: Age ≥ 18 years; active SLE; SLEDAI-2 K score ≥ 6 at screening; clinical SLEDAI-2 K score ≥ 4 at both screening and randomization; moderate to severe rash and/or arthritis by BILAG-2004. Exclusion: Severe active lupus nephritis; active CNS lupus. | Mean age 39.7 years; Gender, %: female (92%); male (8%). | Mean ± SD from baseline in pain domain (RCI vs placebo: week 8 (17.6 ± 24.8 vs 12.2 ± 24.4; P = NS); week 16 (20.6 ± 23.8 vs 12.4 ± 24.1; P < 0.05); week 24 (22.4 ± 25.9 vs 157 ± 26.3; P = NS). | Mean ± SD from baseline in fatigue domain (RCI vs placebo: week 8 (10.5 ± 19.4 vs 11.8 ± 24.0; P = NS); week 16 (12.9 ± 25.9 vs 9.0 ± 24.0; P = NS); week 24 (15.9 ± 25.2 vs 10.1 ± 27.3; P = NS). | Post hoc analyses of RCI vs placebo: RCI group had greater improvements from baseline in pain domain in patients with higher disease activity scores (i.e., SLEDAI-2 K ≥ 10 at week 16, CLASI-Activity ≥ 11 and BILAG-2004 ≥ 20 at week 24, and BICLA responders at week 16); and in fatigue domain in patients with SLEDAI-2 K ≥ 10 and CLASI-Activity ≥ 11 at week 16. |

ACR American College of Rheumatology, bDMARD biologic disease-modifying antirheumatic drug, BICLA BILAG-based combined lupus assessment, BILAG British Isles Lupus Assessment Group, CDAI clinical disease activity index, CNS central nervous system, csDMARD conventional synthetic disease-modifying antirheumatic drug, DAS28 disease activity score for RA, DM/PM dermatomyositis/polymyositis, EMR electronic medical record, ESR erythrocyte sedimentation rate, EULAR European League Against Rheumatism, FACIT-F functional assessment of chronic illness therapy-fatigue, HAQ health assessment questionnaire, MCID minimum clinically important difference, LDA low disease activity, NS not significant, ntDMARD nontraditional disease-modifying antirheumatic drug, PGA physician global assessment, PRO patient-reported outcome, QOL quality of life, RA rheumatoid arthritis, RCI repository corticotropin injection, SLE systemic lupus erythematosus, SLEDAI-2 K SLE Disease Activity Index-2000, SRI-4 SLE Responder Index-4, TJC total joint count, tsDMARD targeted synthetic disease-modifying antirheumatic drug, VAS visual analog scale

*LupusQOL includes eight domains (body image, burden to others, emotional health, fatigue, intimate relationships, pain, physical health, planning); here we report data only for the pain and fatigue domains.*
Table 2: Studies with pain and/or fatigue outcomes following RCI treatment in patients with symptomatic sarcoidosis

| Study            | Objective, design, and treatment                                                                 | Outcomes and sample size                                                                 | Key inclusion/exclusion criteria                                                                 | Patient baseline characteristics                                                                 | Fatigue outcomes                                                                 | Pain outcomes |
|------------------|------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------|----------------|
| Baughman et al. 2017[15] | **Objective:** To compare 2 doses of RCI in patients with advanced pulmonary sarcoidosis receiving prednisone
**Design:** Prospective randomized study
**Treatment:** RCI 80 U SC once a day for 10 days; 14 days after starting study (4 days after last scheduled dose), patients randomized 1:1 to 40 or 80 U RCI twice per week for 22 more weeks | **Primary endpoint:** Prednisone-sparing effect of RCI 40 IU vs 80 IU at week 7 (assessed modification of prednisone dose based on algorithm established by Baughman et al., 2002[35])
**Fatigue and/or pain outcome(s):** KSQ; SGRQ; FAS; steroid toxicity questionnaire
**No. of patients:** Enrolled ($N = 18$); randomized to RCI 40 U ($n = 9$) and randomized to RCI 80 U ($n = 8$) | **Inclusion:** Diagnosis of pulmonary sarcoidosis based on standard ATS/ERS/WASOG criteria[36]; stable dose ≥ 5 mg prednisone for ≥ 3 months; deterioration of pulmonary disease in previous year
**Exclusion:** Received anti-TNF antibody (e.g., infliximab, adalimumab) in prior 6 months; or receiving treatment for sarcoidosis-associated pulmonary hypertension | Median age, years (range): 40 U group, 58 (49–68); 80 U group, 59 (35–60)
Gender (all patients): female (56%); male (44%)
Use of prednisone: 100%
Median FAS (range): week 0, 28 (15–46); week 7, 26 (10–27); week 24, 22 (11–42); week 0 vs week 24, $P = 0.0067$ | None |
Table 2 continued

| Study                          | Objective, design, and treatment                                                                 | Outcomes and sample size | Key inclusion/exclusion criteria                                                                 | Patient baseline characteristics | Fatigue outcomes                                                                 | Pain outcomes |
|-------------------------------|-------------------------------------------------------------------------------------------------|--------------------------|---------------------------------------------------------------------------------------------------|---------------------------------|----------------------------------------------------------------------------------|---------------|
| Chopra et al., 2019 [27]      | **Objective:** To describe patient demographic and clinical characteristics, RCI utilization patterns and concomitant therapies, physicians’ assessments of RCI effects on patients’ health status | **Primary endpoint:** No predefined primary endpoint/outcome | **Inclusion:** Age ≥ 18 years; diagnosis of symptomatic sarcoidosis; treatment with RCI in previous 36 months; completely accessible medical record; completed individualized RCI course (based on disease severity and initial response) or received RCI ≥ 6 months at time of data collection | **Exclusion:** Absence of symptoms | Mean ± SD age 51 ± 12 years; Gender: women (52%); men (48%) | None          |
|                               | **Design:** Retrospective chart review                                                        | **Fatigue and/or pain outcome(s):** Physicians’ assessments of change in patients’ health status after RCI therapy | **Medications in prior 3 months (before starting RCI) for symptomatic sarcoidosis:** oral corticosteroids (61%); biologics (24%); antimalarial agents (22%) | **Present before RCI initiation:** fatigue (42%) | Physicians’ assessments of change in patients’ health post RCI |               |
|                               | **Treatment:** RCI real-world use: Mean ± SD duration of RCI treatment 32.5 ± 35.6 weeks; 62% of patients continued RCI for ≥ 6 months | **No. of patients:** N = 302 | **Type of treatment response that improved due to RCI treatment:** fatigue (29%) | **Patient current status:** Improved (95%); not improved (5%) |                                                                     |               |

ATS American Thoracic Society, ERS European Respiratory Society, FAS fatigue assessment scale, GHS general health status, KSQ King’s sarcoidosis questionnaire, QOL quality of life, RCI repository corticotropin injection, SC subcutaneously, SGRQ Saint George’s respiratory questionnaire, TNF tumor necrosis factor, VAS visual analog scale, WASOG World Association of Sarcoidosis and other Granulomatous Disorders
Table 3  Studies with pain and/or fatigue outcomes following RCI treatment in patients with noninfectious keratitis and uveitis

| Study | Objective, design, and treatment | Outcomes and sample size | Key inclusion/exclusion criteria | Patient baseline characteristics | Fatigue outcomes | Pain outcomes |
|-------|---------------------------------|--------------------------|---------------------------------|---------------------------------|-----------------|--------------|
| Uveitis | Nelson et al., 2019 [22] | Primary endpoint: No predefined primary endpoint/outcome | Inclusion: Diagnosis of uveitis; received RCI in past 12 mo; completed course of RCI or receiving RCI at time of collection; complete medical records available | Mean ± SD age 41 ± 14 years | None | Physicians’ impressions of therapeutic response after RCI injection (% patients): Patient’s current status: Improved (84%); same (19%); worsened (0) |
| | | Fatigue and/or pain outcome(s): Physicians’ impressions of therapeutic response (2 questions: What is the patient’s current status? Please select outcomes that have improved as a result of RCI treatment) | Exclusion: Infectious eye inflammation; ophthalmic neoplasm; recent ophthalmic or orbital surgery (within 60 days before diagnosis); recent eye trauma (within 60 days before diagnosis) | Gender: female (62%); male (38%) | Outcomes that had improved as a result of RCI treatment: Improvements in pain (27%)

Noninfectious keratitis

| Wirta et al., 2021 [16] | Study objective: To evaluate the efficacy and safety of RCI for the treatment of refractory severe noninfectious keratitis that had not adequately responded to treatment with standard-of-care therapies | Primary endpoint: Proportion of patients with ≥12-point improvement in symptom bother domain of IDEEL questionnaire at week 12 and proportion of patients with ≥2%, 3%, and 50% improvement in symptom bother domain of IDEEL questionnaire at week 12 | Inclusion: Age ≥ 18 years; normal lid anatomy; history of severe keratitis in 1 or both eyes and history of previous treatment for keratitis within previous 6 months; no symptomatic improvement or did not tolerate previous treatment with topical cyclosporine or lifitegrast; in ≥ 1 eye at screening and baseline have all of the following: inferior corneal fluorescein staining score ≥ 2 in any field, corneal sum fluorescein staining score ≥ 4, conjunctival sum lissamine green staining score ≥ 2, conjunctival redness score ≥ 1, Schirmer score ≥ 1 mm/5 min and ≤ 10 mm/5 min, and ODS ≥ 2 | Mean ± SD age 63 ± 10 years | None | Proportion of patients with complete resolution of ODS at week 12: 20.0% (95% CI 6.7–33.9%)

ODS = ocular discomfort score; SC = subcutaneously; VAS = visual analog scale

IDEEL: impact of dry eye on everyday life; LASIK = laser-assisted in situ keratomileusis; ODS = ocular discomfort score; RCI = repository corticotropin injection; SC = subcutaneously; VAS = visual analog scale
PROs such as pain VAS. The analyzed patients (mean age 60.1 years) were predominantly women (81%) and had a mean ± SD CDAI score of 29.7 ± 16.4, above the > 22 threshold for high disease activity [28, 29]. Most of these patients had been treated with a DMARD (96%) and glucocorticoids (92%). The 46% of patients with at least two RCI prescriptions had a mean ± SD of 152 ± 117 days lapsing from the start of RCI to the last RCI prescription. Compared with before starting RCI, the patients’ mean ± SD pain VAS severity score significantly decreased (mean decrease - 1.1 ± 2.8; \( P = 0.0056 \)) after starting RCI.

Fiechtner and Montroy [12] assessed FACIT-F at baseline and after RCI treatment initiation in a prospective open-label clinical trial of RCI in 10 adults with chronic moderately-to-severely active SLE flares despite standard treatment. The patients (median age 49 years) were all women, with a mean baseline SLEDAI-2 K score of 10. RCI treatment consisted of 80 U daily for 10 days, followed by an optional 5-day rescue period for patients experiencing partial or no response. These investigators reported statistically significant improvements in mean FACIT-F scores at day 14 and day 28 (both \( P < 0.01 \)) after the start of RCI treatment compared with baseline.

One study included PRO data for both pain and fatigue [14, 25]. As part of a 24-week randomized, double-blind, clinical trial comparing RCI with placebo in 169 adults with persistently active SLE despite use of moderate-dose glucocorticoids, Askanase et al. [14, 25] reported findings at baseline and weeks 8, 16, and 24 using the LupusQOL PRO instrument, which measures fatigue, pain, and six other domains (body image, burden to others, emotional health, intimate relationships, physical health, and planning). The enrolled patients (median age 39.7 years) were predominantly women and had a mean SLEDAI-2 K score of 9.9. Patients were randomized to receive RCI 80 U or placebo every other day through week 4, then twice per week for 20 more weeks, for a total of 24 weeks. Patients in the RCI group had greater improvement compared with the placebo group in mean ± SD change from baseline for the LupusQOL pain domain at week 16 (mean, 20.6 ± 23.8 vs 12.4 ± 24.1; \( P < 0.05 \)) and no statistically significant differences in the fatigue domain at weeks 8, 16, and 24. Exploratory post hoc subgroup analyses found greater improvements from baseline for RCI compared with placebo in LupusQOL pain and fatigue domains among patients who had higher disease activity as indicated by SLEDAI-2 K \( \geq 10 \), CLASI-Activity \( \geq 11 \), and/or BICLA. These improvements were above thresholds considered to indicate minimal clinically important difference (MCID) in patients with SLE [34].

**Impact of RCI on Pain and Fatigue in Sarcoidosis**

Two studies used PROs and/or physician-reported pain or fatigue measures in patients with sarcoidosis (Table 2) [15, 27]. In a prospective randomized study comparing two doses of RCI in 18 patients with pulmonary sarcoidosis, Baughman et al. [15] included PRO data from FAS at baseline and weeks 7 and 24 after initiation of RCI treatment. The patients had a median age of 59 years; most were women (56%), and all were using prednisone to treat sarcoidosis. All the patients were treated with RCI 80 U once a day for 10 days and, 4 days after the last scheduled dose, they were randomized 1:1 to continue treatment with RCI 40 or 80 U twice a week for 22 more weeks. The investigators reported data on the total patient population because they did not find statistically significant differences between the two RCI dosing groups. The median FAS significantly improved (\( P = 0.0067 \)) from baseline (median 28, range 15–46) to 24 weeks after the start of RCI treatment (median 22, range 11–42).

A retrospective chart review by Chopra et al. [27] of data from 302 adults with sarcoidosis treated with RCI during the previous 36 months reported physicians’ assessments of patients’ response status by outcome domain (i.e., improved or not improved at the end of RCI therapy or of the prior 6 months if RCI was ongoing) and by type of treatment outcome (selecting from nine options, including fatigue) that had improved with RCI treatment. Patients had a mean ± SD age of 51 ± 12 years, 52%
were women, and 42% presented with fatigue before initiating RCI therapy. Most patients (61%) had been treated with oral corticosteroids for symptomatic sarcoidosis during the 3 months before initiating RCI therapy. The study did not report information on RCI dosing; the mean ± SD duration of RCI treatment was 32 ± 36 weeks, and 62% of patients continued to take RCI for at least 6 months. According to physicians’ assessments, 29% of patients experienced improvement in fatigue after initiating RCI treatment.

**Impact of RCI on Pain and Fatigue in Uveitis and Keratitis**

Two studies included findings on PRO and/or physician-reported pain or fatigue measures in patients with uveitis or noninfectious keratitis (Table 3) [16, 22]. In a retrospective chart review of 91 patients with uveitis treated in the previous 12 months, Nelson et al. [22] reported data on physicians’ assessments of patient’s current status after RCI injection and type of observed improvements, including improvements in pain. Patients in this study had a mean ± SD age of 41 ± 14 years and were predominantly women (62%). The most common uveitis symptoms reported in these patients were blurred vision (89%), light sensitivity (45%), floaters (44%), visual loss/acuity (44%), and eye pain (37%). Most patients (77%) had been prescribed an RCI initial regimen of 40 to 80 U once or twice weekly. The dosing and course of treatment varied. After RCI injection, physicians’ assessments noted improvements in 84% of patients’ current status, primarily because of improvements in vision (86%) and improvements in pain (27%).

In a prospective open-label phase 4 trial in adults with severe noninfectious keratitis, Wirta et al. [16] reported data on PROs such as ODS, the four-symptom questionnaire (which included assessments of burning and stinging), and eye-specific VAS measures (which also included assessment of burning/stinging and pain). The enrolled patients (mean age 63 years) were predominantly women (71%), and all had keratitis in both eyes. Patients received RCI 80 U twice weekly for 12 weeks followed by a tapering sequence of 2 weeks of 40 U twice weekly and 2 weeks of 40 U once weekly. At week 12, 20% of patients had experienced complete resolution of ODS. According to the four-symptom questionnaire at week 12, 43% of patients had complete resolution of burning and 63% of stinging. The mean ± SD change from baseline by VAS at week 12 was −13.5 ± 24.3 (95% CI −23.3 to −3.7) for burning/stinging and −15.0 ± 20.2 (95% CI −23.1 to −6.9) for pain.

**DISCUSSION**

Across the different types of studies assessed (i.e., clinical trials, chart reviews, EMR real-world evidence) in this narrative review, the results were consistent with respect to the impact of RCI treatment on reducing pain and fatigue, regardless of whether the studies were open-label or randomized and blinded, analogous to the results obtained with other efficacy outcome measures.

In the four RA or SLE studies, patients were predominantly women (81–100%) with high disease activity despite ongoing treatment with DMARDs and other drugs [11, 12, 14, 23, 26]. In all four studies, either pain or fatigue was reduced and in two of the studies, both pain and FACIT-F were improved in responders or those with high disease activity. At the end of 12 weeks of open-label RCI treatment in a randomized withdrawal study in patients with active RA, the statistically significant decreases in mean FACIT-F scores and PGAP paralleled the finding that 62.9% of patients achieved the primary endpoint of DAS28-ESR < 3.2 and 65.3% achieved CDAI LDA (i.e., CDAI ≤ 10) [11, 31, 37]. An EMR analysis of data from 114 patients noted that, after the RCI index date, the significant decrease in pain VAS severity aligned with a clinically meaningful reduction in CDAI mean scores (−9.7 ± 16.9, P = 0.0101), changing high RA activity to moderate RA activity, and with significant decreases in swollen (−1.1 ± 2.8; P = 0.0116) and tender joint mean counts (−3.3 ± 8.0; P = 0.0128) [23]. A small single-group clinical
trial reported significant improvements in mean FACIT-F scores from baseline to days 14 and 28 following RCI treatment initiation [12] in addition to significant improvements in the primary endpoint of mean SLEDAI-2 K, which decreased from 9.6 at baseline to 6.2 at day 14 and 4.0 at day 28 after RCI initiation (both comparisons $P < 0.01$).

In the two studies assessing pain and/or fatigue after treatment with RCI in adults with symptomatic sarcoidosis, the combined analysis of a randomized study of two doses of RCI reported significant improvements in median FAS from baseline to 24 weeks after RCI initiation ($P = 0.0067$) along with significant decreases in prednisone dosage ($P = 0.0078$) and other clinical efficacy measures, such as median standard uptake value of highest lung lesion [15]. A large retrospective chart review reported that by physicians’ assessments of change in patients’ health post-RCI treatment, 95% of patients with symptomatic sarcoidosis had improved because of treatment responses in overall symptoms (73%); lung function (38%); inflammation (33%); corticosteroid use, reduction, or discontinuation (32%); QOL (32%); and fatigue (29%) [28].

A retrospective chart review of patients with uveitis reported that physicians’ assessments of patients’ current health status showed improvements in 84% of patients, as marked by improvements in vision (86%), improvements in pain (27%), and improvements in vitreous haze (26%) [22], which translated to reductions in use of concomitant medications such as steroid eye drops, oral steroids, and intraocular steroids [22]. A prospective single-arm clinical trial in patients with severe keratitis reported meaningful mean changes from baseline to week 12 of RCI treatment for the VAS burning/stinging and pain measures and 50% of patients in the study met the primary endpoint of clinically important improvements (i.e., at least 12 points) in the symptom bother domain of the IDEEL questionnaire [16, 38].

CONCLUSIONS

As summarized in this review, data from patient- and physician-reported outcome measures in eight published studies suggest that, in addition to improving more traditional efficacy measures, RCI may also improve pain and fatigue outcomes in patients with RA, SLE, symptomatic sarcoidosis, uveitis, and noninfectious keratitis. To evaluate treatment effectiveness in future studies in these populations, pain and fatigue measures should be considered for inclusion alongside conventional efficacy assessments.

ACKNOWLEDGEMENTS

Funding. The development of this manuscript and the journal’s rapid service and open access fees were funded by Mallinckrodt Pharmaceuticals, Hampton, NJ, USA.

Authorship. All named authors meet the International Committee of Medical Journal Editors (ICMJE) criteria for authorship for this article, take responsibility for the integrity of the work as a whole, and have given their approval for this version to be published.

Author Contributions. GW had the idea for the article. JN performed the literature search. CG, MPP, KH, JN, and GW drafted and/or critically revised the work.

Medical Writing, Editorial, and Other Assistance. Monica Nicosia, PhD, and Esther Tazartes, MS, of Global Outcomes Group provided medical writing and editorial assistance, which was funded by Mallinckrodt Pharmaceuticals, Hampton, NJ, USA.

Disclosures. Cynthia Girman and Mary P. Panaccio are paid independent consultants of Mallinckrodt Pharmaceuticals, Hampton, NJ, USA. Kyle Hayes, John Niewoehner, and George J. Wan are employees of Mallinckrodt Pharmaceuticals, Hampton, NJ, USA. At the time of this
writing, all the authors declare that they have nothing else to disclose.

Compliance with Ethics Guidelines. This article is based on previously conducted studies and does not contain any new studies of human participants or animals performed by any of the authors.

Data Availability. Data sharing is not applicable to this article because no datasets were generated or analyzed during the current study.

Open Access. This article is licensed under a Creative Commons Attribution-Non-Commercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/.

REFERENCES

1. Vergne-Salle P, Pouplin S, Trouvin AP, et al. The burden of pain in rheumatoid arthritis: impact of disease activity and psychological factors. Eur J Pain. 2020;24:1979–89.

2. Overman CL, Kool MB, Da Silva JA, Geenen R. The prevalence of severe fatigue in rheumatic diseases: an international study. Clin Rheumatol. 2016;35: 409–15.

3. Davies K, Dures E, Ng WF. Fatigue in inflammatory rheumatic diseases: current knowledge and areas for future research. Nat Rev Rheumatol. 2021;17: 651–64.

4. O’Brien CM, Ntoumanis N, Duda JL, et al. Pain and fatigue are longitudinally and bi-directionally associated with more sedentary time and less standing time in rheumatoid arthritis. Rheumatology (Oxford). 2021;60:4548–57.

5. Azizoddin DR, Gandhi N, Weinberg S, Sengupta M, Nicassio PM, Jolly M. Fatigue in systemic lupus: the role of disease activity and its correlates. Lupus. 2019;28:163–73.

6. Choy EH. Effect of biologics and targeted synthetic disease-modifying anti-rheumatic drugs on fatigue in rheumatoid arthritis. Rheumatology (Oxford). 2019;58:v51–5.

7. Ho-Mahler N, Turner B, Eaddy M, Hanke ML, Nelson WW. Treatment with repository corticotropin injection in patients with rheumatoid arthritis, systemic lupus erythematosus, and dermatomyositis/polymyositis. Open Access Rheumatol. 2020;12: 21–8.

8. Acthar Gel (repository corticotropin injection). Prescribing information. Mallinckrodt Pharmaceuticals. 2021. https://www.acthar.com/pdf/Acthar_PI.pdf. Accessed Oct 2021.

9. Gillis T, Crane M, Hinkle C, Wei N. Repository corticotropin injection as adjunctive therapy in patients with rheumatoid arthritis who have failed previous therapies with at least three different modes of action. Open Access Rheumatol. 2017;9: 131–8.

10. Fischer PA, Rapoport RJ. Repository corticotropin injection in patients with rheumatoid arthritis resistant to biologic therapies. Open Access Rheumatol. 2018;10:13–9.

11. Fleischmann R, Furst DE, Connolly-Strong E, Liu J, Zhu J, Brasington R. Repository corticotropin injection for active rheumatoid arthritis despite aggressive treatment: a randomized controlled withdrawal trial. Rheumatol Ther. 2020;7:327–44.

12. Flechtner JJ, Montroy T. Treatment of moderately to severely active systemic lupus erythematosus with adrenocorticotropic hormone: a single-site, open-label trial. Lupus. 2014;23:905–12.

13. Furie R, Mitrane M, Zhao E, Das M, Li D, Becker PM. Efficacy and tolerability of repository corticotropin injection in patients with persistently active SLE: results of a phase 4, randomised, controlled pilot study. Lupus Sci Med. 2016;3: e000180.

14. Askanase AD, Zhao E, Zhu J, Bilyk R, Furie RA. Repository corticotropin injection for persistently active systemic lupus erythematosus: results from a phase 4, multicenter, randomized, double-blind,
15. Baughman RP, Sweiss N, Keijser R, et al. Repository corticotropin for chronic pulmonary sarcoidosis. Lung. 2017;195:313–22.

16. Wirta D, McLaurin E, Ousler G, Liu J, Kacmaz RO, Grieco J. Repository corticotropin injection (Acthar® Gel) for refractory severe noninfectious keratitis: efficacy and safety from a phase 4, multicenter, open-label study. Ophthalmol Ther. 2021;10:1077–92.

17. Brown AN. Repository corticotropin injection in patients with refractory psoriatic arthritis: a case series. Open Access Rheumatol. 2016;8:97–102.

18. Li X, Golubovsky J, Hui-Yuen J, et al. Adrenocorticotropic hormone gel in the treatment of systemic lupus erythematosus: A retrospective study of patients. [version 2; peer review: 2 approved]. F1000Res. 2016;2:4.

19. Baughman RP, Barney JB, O’Hare L, Lower EE. A retrospective pilot study examining the use of Acthar gel in sarcoidosis patients. Respir Med. 2016;110:66–72.

20. Nelson WW, Philbin MJ, Gallagher JR, Heap K, Carroll S, Wan GJ. A retrospective medical record review of utilization patterns and medical resource use associated with repository corticotropin injection among patients with rheumatologic diseases in the United States. Rheumatol Ther. 2017;4:465–74.

21. Nelson WW, Lima AF, Kranyak J, et al. Retrospective medical record review to describe use of repository corticotropin injection among patients with uveitis in the United States. J Ocul Pharmacol Ther. 2019;35:182–8.

22. Hayes K, Panaccio MP, Houston P, et al. Real-world treatment patterns and outcomes from an electronic medical records database for patients with rheumatoid arthritis treated with repository corticotropin injection. Open Access Rheumatol. 2021;13:315–23.

23. Myung G, Nelson WW, McMahon MA. Effects of respiratory corticotropin injection on medication use in patients with rheumatologic conditions: a claims data study. J Pharm Technol. 2017;33:151–5.

24. Wu B, Deshpande G, Gu T, Popelar B, Philbin M, Wan GJ. Demographics, treatment patterns, and healthcare utilization and cost of repository corticotropin injection in patients with systemic lupus erythematosus or rheumatoid arthritis. J Med Econ. 2017;20:1170–7.

25. Askanas AD, Wan GJ, Panaccio MP, et al. Patient-reported outcomes from a phase 4, multicenter, randomized, double-blind, placebo-controlled trial of repository corticotropin injection (Acthar® Gel) for persistently active systemic lupus erythematosus. Rheumatol Ther. 2021;8:573–84.

26. Fleischmann R, Hayes K, Ahn SW, et al. Post hoc analysis of the correlation between patient-reported outcomes and clinical response to repository corticotropin injection for persistently active rheumatoid arthritis. Rheumatol Ther. 2022;9:435–46.

27. Chopra I, Qin Y, Kranyak J, et al. Repository corticotropin injection in patients with advanced symptomatic sarcoidosis: retrospective analysis of medical records. Ther Adv Respir Dis. 2019;13:175346619888127.

28. Alethea D, Smolen J. The Simplified Disease Activity Index (SDAI) and the Clinical Disease Activity Index (CDAI): a review of their usefulness and validity in rheumatoid arthritis. Clin Exp Rheumatol. 2005;23:S100–8.

29. Singh JA, Saag KG, Bridges SL Jr, et al. 2015 American College of Rheumatology guideline for the treatment of rheumatoid arthritis. Arthritis Rheumatol. 2016;68:1–26.

30. Wolfe F, Michaud K. Assessment of pain in rheumatoid arthritis: minimal clinically significant difference, predictors, and the effect of anti-tumor necrosis factor therapy. J Rheumatol. 2007;34:1674–83.

31. Fleischmann R, Furst D, Wan G, et al. Efficacy and patient-reported outcome measures from a two-part multicenter, placebo-controlled, randomized withdrawal trial of repository corticotropin injection for persistently active rheumatoid arthritis. Ann Rheum Diseases. 2020;79:642.

32. Wells GA, Tugwell P, Kraag GR, Baker PR, Groh J, Redelmeier DA. Minimum important difference between patients with rheumatoid arthritis: the patient’s perspective. J Rheumatol. 1993;20:557–60.

33. Cella D, Yount S, Sorensen M, Chartash E, Sengupta N, Grober J. Validation of the Functional Assessment of Chronic Illness Therapy Fatigue Scale relative to other instrumentation in patients with rheumatoid arthritis. J Rheumatol. 2005;32:811–9.

34. McElhone K, Abbott J, Sutton C, et al. Sensitivity to change and minimal important differences of the LupusQoL in patients with systemic lupus erythematosus. Arthritis Care Res (Hoboken). 2016;68:1505–13.

35. Baughman RP, Iannuzzi MC, Lower EE, et al. Use of fluticasone in acute symptomatic pulmonary...
sarcoidosis. Sarcoïdosis Vasc Diffuse Lung Dis. 2002;19:198–204.

36. Hunninghake GW, Costabel U, Ando M, et al. ATS/ERS/WASOG statement on sarcoidosis. American Thoracic Society/European Respiratory Society/World Association of Sarcoïdosis and other Granulomatous Disorders. Sarcoïdosis Vasc Diffuse Lung Dis. 1999;16:149–73.

37. Furst D, Wan G, Liu J, et al. Improved patient-reported outcomes in patients with persistently active rheumatoid arthritis following treatment with repository corticotropin injection (abstract 439). Arthritis Rheumatol. 2019;71:725–7.

38. Fairchild CJ, Chalmers RL, Begley CG. Clinically important difference in dry eye: change in IDEEL-symptom bother. Optom Vis Sci. 2008;85:699–707.